Basal forebrain cholinergic lesion by 192 IgG-saporin a tool to assess the consequences of cortical cholinergic dysfunction in alzheimer's disease

Molecular Neurosurgery With Targeted Toxins

Volumn , Issue , 2005, Pages 59-86

  Schliebs, Reinhard ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33750442795     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-59259-896-0_4     Document Type: Chapter

References (154)

1. Bartus RT, Dean RL, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982;217:408-414.
2. Coyle JT, Price DL, De Long MR. Alzheimer's disease: a disorder of cortical cholinergic innervation. Science 1983;219:1184-1190.
3. Bartus RT. On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp Neurol 2000;163:495-529.
4. Francis PT, Palmer AM, Snape M, Wxsilcock GK. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry 1999;66:137-147.
5. Palmer AM. Pharmacotherapy of Alzheimer's disease: progress and prospects. Trends Pharmacol Sci 2002;23:426-433.
6. Bierer LM, Haroutunian V, Gabriel S, et al. Neurochemical correlates of dementia severity in Alzheimer's disease: relative importance of the cholinergic deficits. J Neurochem 1995;64:749-760.
7. Apelt J, Schliebs R, Beck M, Roßner S, Bigl V. Expression of amyloid precursor protein mRNA isoforms in rat brain is differentially regulated during postnatal maturation and by cholinergic activity. Int J Dev Neurosci 1997;15:95-112.
8. Leanza G. Chronic elevation of amyloid precursor protein expression in the neocortex and hippocampus of rats with selective cholinergic lesions. Neurosci Lett 1998;257:53-66.
9. Lin L, Le Blanc CJ, Deacon TW, Isacson O. Chronic cognitive deficits and amyloid precursor protein elevation after selective immunotoxin lesions of the basal forebrain cholinergic system. Neuroreport 1998;9:547-552.
10. Lin L, Georgievska B, Mattsson A, Isacson O. Cognitive changes and modified processing of amyloid precursor protein in the cortical and hippocampal system after cholinergic synapse loss and muscarinic receptor activation. Proc Natl Acad Sci USA 1999;96:12, 108-12, 113.
11. Lin L, Georgievska B, Mattsson A, Browne SE, Isacson O. In vivo regulation of amyloid precursor protein processing by mucarinic receptor activation and regional reductions in glucose utilization in rats with cholinergic deficits. Soc Neurosci Abstr 1999;25:2054.
12. Nitsch RM, Deng M, Growdon JH, Wurtman RJ. Serotonin 5-HT2a and 5-HT2c receptors stimulate amyloid precursor protein ectodomain secretion. J Biol Chem 1996;271:4188-4194.
13. Muller DM, Mendla K, Farber SA, Nitsch RM. Muscarinic M1 receptor agonists increase the secretion of the amyloid precursor protein ectodomain. Life Sci 1997;60:985-991.
14. Roßner S, Wortwein G, Gu Z, et al. Cholinergic control of nerve growth factor in adult rats: evidence from cortical cholinergic deafferentation and chronic drug treatment. J Neurochem 1997;69:947-953.
15. Roßner S, Ueberham U, Schliebs R, Perez-Polo JR, Bigl V. The regulation of amyloid precursor protein metabolism by cholinergic mechanisms and neurotrophin receptor signaling. Prog Neurobiol 1998;56:541-569.
16. Härtig W, Bauer A, Brauer K, et al. Functional recovery of cholinergic basal forebrain neurons under disease conditions: old problems, new solutions? Rev Neurosci 2002;13:95-165.
17. Schliebs R, Roßner S, Bigl V. Immunolesion by 192 IgG-saporin of rat basal forebrain cholinergic system: a useful tool to produce cortical cholinergic dysfunction. Progr Brain Res 1996;109:253-264.
18. Krügel U, Bigl V, Eschrich K, Bigl M. Deafferentation of the septo-hippoc-ampal pathway in rats as model of the metabolic events in Alzheimer's disease. Int J Dev Neurosci 2001;19:263-277.
19. Bigl V, Schliebs R. Simulation of cortical cholinergic deficits-a novel experimental approach to study pathogenetic aspects of Alzheimer's disease. J Neural Transm 1998;54(suppl):237-247.
20. Wrenn CC, Wiley RG. The behavioral functions of the cholinergic basal fore-brain: lessons from 192 IgG-saporin. Int J Dev Neurosci 1998;16:595-602.
21. Wiley RG, Kline RH IV. Neuronal lesioning with axonally transported toxins. J Neurosci Methods 2000;103:73-82.
22. Wenk GL, Harrington CA, Tucker DA, Rance NE, Walker LC. Basal fore-brain neurons and memory: a biochemical, histological, and behavioral study of differential vulnerability to ibotenate and quisqualate. Behav Neurosci 1992;106:909-923.
23. Hanin I. Cholinergic toxins and Alzheimer's disease. Ann NY Acad Sci 1992;648:63-70.
24. Wiley RG. Neural lesioning with ribosome-inactivating proteins: suicide transport and immunolesioning. Trends Neurosci 1992;15:285-290.
25. Barefoot HC, Baker HF, Ridley RM. Synergistic effects of unilateral immunolesions of the cholinergic projections from the basal forebrain and contralateral ablations of the inferotemporal cortex and hippocampus in monkeys. Neuroscience 2000;98:243-251.
26. Berger-Sweeney J, Stearns NA, Murg SL, Floerke-Nashner LR, Lappi DA, Baxter MG. Selective immunolesions of cholinergic neurons in mice: effect on neuroanatomy, neurochemistry, and behavior. J. Neurosci 2001;21:8164-8173.
27. Tremere LA, Pinaud R, Grosche J, Härtig W, Rasmusson DD. Antibody for human p75LNTR identifies cholinergic basal forebrain non-primate species. Neuroreport 2000;11:2177-2183.
28. McGaughy J, Everitt BJ, Robbins TW, Sarter M. The role of cortical cholin-ergic afferent projections in cognition: impact of new selective immunotoxins. Behav Brain Res 2000;115:251-263.
29. Hartlage-Rübsamen M, Schliebs R. Rat basal forebrain cholinergic lesion affects neuronal nitric oxide synthase in cholinoceptive hippocampal and neo-cortical target regions. Brain Res 2001;889:155-164.
30. Hartlage-Rübsamen M, Schliebs R. Sequential upregulation of cell adhesion molecules in degenerating rat basal forebrain cholinergic neurons and in ph-agocytic microglial cells. Brain Res 2001;897:20-26.
31. Lemke R, Hartlage-Rübsamen M, Schliebs R. Differential injury-dependent glial expression of interleukins-1alpha, beta and interleukin-6 in rat brain. Glia 1999;27:75-87.
32. Wiley RG, Oeltmann TN, Lappi DA. Immunolesioning: selective destruction of neurons using immunotoxin to rat NGF receptor. Brain Res 1991;562:149-153.
33. Gage FH, Batchelor P, Chen KS, et al. NGF receptor reexpression and NGF-mediated cholinergic neuronal hypertrophy in the damaged adult neostriatum. Neuron 1989;2:1177-1184.
34. Yan Q, Johnson EM Jr. Immunohistochemical localization and biochemical characterization of nerve growth factor receptor in adult rat brain. J Comp Neurol 1989;290:585-598.
35. Thomas LB, Book AA, Schweitzer JB. Immunohistochemical detection of a monoclonal antibody directed against the NGF receptor in basal forebrain neurons following intraventricular injection. J Neurosci Methods 1991;37:37-45.
36. Berger-Sweeney J, Heckers S, Mesulam MM, Wiley RG, Lappi DA, Sharma M. Differential effects on spatial navigation of immunotoxin-induced cholin-ergic lesions of the medial septal area and nucleus basalis magnocellularis. J Neurosci 1994;14:4507-4519.
37. Book AA, Wiley RG, Schweitzer JB. Specificity of 192 IgG-saporin for NGF receptor-positive cholinergic basal forebrain neurons in the rat. Brain Res 1992;590:350-355.
38. Heckers S, Ohtake T, Wiley RG, Lappi DA, Geula C, Mesulam MM. Complete and selective cholinergic denervation of rat neocortex and hippocampus but not amygdala by an immunotoxin against the p75 NGF receptor. J Neurosci 1994;14:1271-1289.
39. Rossner S, Perez-Polo JR, Wiley RG, Schliebs R, Bigl V. Differential expression of immediate early genes in distinct layers of rat cerebral cortex after selective immunolesion of the forebrain cholinergic system. J Neurosci Res 1994;38:282-293.
40. Roßner S, Schliebs R, Perez-Polo JR, Wiley RG, Bigl V. Differential changes in cholinergic markers from selected brain regions after specific immunolesion of rat cholinergic basal forebrain system. J Neurosci Res 1995;40:31-43.
41. Roßner S, Härtig W, Schliebs R, et al. 192 IgG-saporin immunotoxin-induced loss of cholinergic cells differentially activates microglia in rat basal fore-brain nuclei. J Neurosci Res 1995;41:335-346.
42. Roßner S, Schliebs R, Härtig W, Bigl V. 192 IgG-saporin-induced selective lesion of cholinergic basal forebrain system: neurochemical effects on cholin-ergic neurotransmission in rat cerebral cortex and hippocampus. Brain Res Bull 1995;38:371-381.
43. Roßner S, Schliebs R, Bigl V. 192 IgG-saporin-induced immunotoxic lesions of cholinergic basal forebrain system differentially affect glutamatergic and GABAergic markers in cortical rat brain regions. Brain Res 1995;696:165-176.
44. Leanza G, Nilsson OG, Wiley RG, Bjorklund A. Selective lesioning of the basal forebrain cholinergic system by intraventricular 192 IgG-saporin: behavioural, biochemical and stereological studies in the rat. Eur J Neurosci 1995;7:329-343.
45. Lee MG, Chrobak JJ, Sik A, Wiley RG, Buzsaki G. Hippocampal theta activity following selective lesion of the septal cholinergic system. Neuroscience 1994;62:1033-1047.
46. Wenk GL, Stoehr JD, Quintana G, Mobley S, Wiley RG. Behavioral, biochemical, histological, and electrophysiological effects of 192 IgG-saporin injections into the basal forebrain of rats. J Neurosci 1994;14:5986-5995.
47. Seeger G, Hartig W, Rossner S, et al. Electron microscopic evidence for mi-croglial phagocytic activity and cholinergic cell death after administration of the immunotoxin 192 IgG-saporin in rat. J Neurosci Res 1997;48:465-476.
48. Book AA, Wiley RG, Schweitzer JB. 192 IgG-saporin: I. Specific lethality for cholinergic neurons in the basal forebrain of the rat. J Neuropathol Exp Neurol 1994;53:95-102.
49. Potter PE, Gaughan C, Assouline Y. Lesion of septal-hippocampal neurons with 192 IgG-saporin alters function of M1 muscarinic receptors. Neurophar-macology 1999;38:579-586.
50. Sorger D, Schliebs R, Kampfer I, et al. In vivo [125I]-iodobenzovesamicol binding reflects cortical cholinergic deficiency induced by specific immunolesion of rat basal forebrain cholinergic system. Nucl Med Biol 2000;27:23-31.
51. Bickel U, Kewitz H. Colocalization of choline acetyltransferase and nerve growth factor receptor in the rat basal forebrain. Dementia 1990;1:146-150.
52. Woolf NJ, Gould E, Butcher LL. Nerve growth factor receptor is associated with cholinergic neurons of the basal forebrain but not the pontomesencephalon. Neuroscience 1989;30:143-152.
53. Butt AE, Bowman TD. Transverse patterning reveals a dissociation of simple and configural association learning abilities in rats with 192 IgG-saporin lesions of the nucleus basalis magnocellularis. Neurobiol Learn Mem 2002;77:211-233.
54. Pizzo DP, Thal LJ, Winkler J. Mnemonic deficits in animals depend upon the degree of cholinergic deficit and task complexity. Exp Neurol 2002;177:292-305.
55. Nicolle MM, Shivers A, Gill TM, Gallagher M. Hippocampal N-methyl-D-aspartate and kainate binding in response to entorhinal cortex aspiration or 192 IgG-saporin lesions of the basal forebrain. Neuroscience 1997;77:649-659.
56. Jouvenceau A, Dutar P, Billard JM. Alteration of NMDA receptor-mediated synaptic responses in CA1 area of the aged rat hippocampus: contribution of GABAergic and cholinergic deficits. Hippocampus 1998;8:627-637.
57. Heider M, Schliebs R, Rossner S, Bigl V. Basal forebrain cholinergic immunolesion by 192 IgG-saporin: evidence for a presynaptic location of sub-populations of a 2- and β-adrenergic as well as 5-HT2A receptors on cortical cholinergic terminals. Neurochem Res 1997;22:957-966.
58. Farr SA, Flood JF, Morley JE. The effect of cholinergic, GABAergic, seroton-ergic, and glutamatergic receptor modulation on posttrial memory processing in the hippocampus. Neurobiol Learn Mem 2000;73:150-167.
59. Kalaria RN, Andorn AC. Adrenergic receptors in aging and Alzheimer's disease: decreased a 2-receptors demonstrated by [3H]p-aminoclonidine binding in prefrontal cortex. Neurobiol Aging 1991;12:131-136.
60. Nordberg A. Neuroreceptor changes in Alzheimer disease. Cerebrovasc Brain Metab Rev 1992;4:303-328.
61. Kalaria RN, Andorn AC, Tabaton M, Whitehouse PJ, Harik SI, Unnerstall JR. Adrenergic receptors in aging and Alzheimer's disease: increased β 2-recep-tors in prefrontal cortex and hippocampus. J Neurochem 1989;53:1772-1781.
62. Shimohama S, Taniguchi T, Fujiwara M, Kameyama M. Changes in β-adren-ergic receptor subtypes in Alzheimer-type dementia. J Neurochem 1987;48:1215-1221.
63. Roßner S, Yu J, Pizzo K, et al. Effects of intraventricular transplantation of NGF-secreting cells on cholinergic basal forebrain neurons after partial immunolesion. J. Neurosci Res 1996;45:40-56.
64. Crutcher KA, Scott SA, Liang S, Everson WV, Weingartner J. Detection of NGF-like activity in human brain tissue: increased levels in Alzheimer's disease. J Neurosci 1993;13:2540-2550.
65. Hellweg R, Gericke CA, Jendroska K, Hartung HD, Cervos-Navarro J. NGF content in the cerebral cortex of non-demented patients with amyloid-plaques and in symptomatic Alzheimer's disease. Int J Dev Neurosci 1998;16:787-794.
66. Rahimi O, Juliano SL. Transplants of NGF-secreting fibroblasts restore stimulus-evoked activity in barrel cortex of basal-forebrain-lesioned rats. J Neurophysiol 2001;86:2081-2096.
67. Rahimi O, Eslin DE, Hill GF II, Juliano SL. Nerve growth factor increases stimulus-evoked metabolic activity in acetylcholine-depleted barrel cortex. Somatosens Mot Res 1999;16:151-162.
68. Martinez-Serrano A, Björklund A. Ex vivo growth factor gene transfer to the basal forebrain in presymptomatic middle-aged rats prevents the development of cholinergic neuron atrophy and cognitive impairment during aging. Proc Natl Acad Sci USA 1998;95:1858-1863.
69. Eriksdotter-Jönhagen M, Nordberg A, Amberla K, et al. Intracerebroven-tricular infusion of nerve growth factor in three patients with Alzheimer's disease. Dement Geriatr Cogn Disord 1998;9:246-257.
70. Winkler J, Ramirez GA, Thal LJ, Waite JJ. Nerve growth factor (NGF) augments cortical and hippocampal cholinergic functioning after p75NGF receptor-mediated deafferentation but impairs inhibitory avoidance and induces fear-related behaviors. J Neurosci 2000;20:834-844.
71. Sofroniew MV, Howe CL, Mobley WC. Nerve growth factor signaling, neuroprotection, and neural repair. Annu Rev Neurosci 2001;24:1217-1281.
72. Tuszynski MH. Intraparenchymal NGF infusions rescue degenerating cholin-ergic neurons. Cell Transplant 2000;9:629-636.
73. Capsoni S, Ugolini G, Comparini A, Ruberti F, Berardi N, Cattaneo A. Alzheimer-like neurodegeneration in aged antinerve growth factor transgenic mice. Proc Natl Acad Sci USA 2000;97:6826-6831.
74. Ruberti F, Capsoni S, Comparini A, et al. Phenotypic knock-out of nerve growth factor in adult transgenic mice reveals severe deficits in basal fore-brain cholinergic neurons, cell death in the spleen, and skeletal muscle dystrophy. J Neurosci 2000;20:2589-2601.
75. Roberson MR, Harrell LE. Cholinergic activity and amyloid precursor protein metabolism. Brain Res Rev 1997;30:50-69.
76. Nitsch RM, Slack BE, Wurtman RJ, Growdon JH. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcho-line receptors. Science 1992;258:304-307.
77. Lee RK, Wurtman RJ, Cox AJ, Nitsch RM. Amyloid precursor protein processing is stimulated by metabotropic glutamate receptors. Proc Natl Acad Sci USA 1995;92:8083-8087.
78. Farber SA, Nitsch RM, Schulz JG, Wurtman RJ. Regulated secretion of beta-amyloid precursor protein in rat brain. J Neurosci 1995;15:7442-7451.
79. Hung AY, Haass C, Nitsch RM, et al. Activation of protein kinase C inhibits cellular production of the amyloid beta-protein. J Biol Chem 1993;268:22, 959-22, 962.
80. Jacobsen JS, Spruyt MA, Brown AM, et al. The release of Alzheimer's disease beta amyloid peptide is reduced by phorbol treatment. J Biol Chem 1994;269:8376-8382.
81. Wallace W, Ahlers ST, Gotlib J, et al. Amyloid precursor protein in the cerebral cortex is rapidly and persistently induced by loss of subcortical innerva-tion. Proc Natl Acad Sci USA 1993;90:8712-8716.
82. Harkany T, Abraham I, Timmermann W, et al. β-amyloid neurotoxicity is mediated by a glutamate-triggered excitotoxic cascade in rat nucleus basalis. Eur J Neurosci 2000;12:2735-2745.
83. Ramirez MJ, Heslop KE, Francis PT, Rattray M. Expression of amyloid precursor protein, tau and presenilin RNAs in rat hippocampus following deaf-ferentation lesions. Brain Res 2001;907:222-232.
84. Haroutunian V, Greig N, Pei XF, et al. Pharmacological modulation of Alzheimer's β-amyloid precursor protein levels in the CSF of rats with fore-brain cholinergic system lesions. Mol Brain Res 1997;46:161-168.
85. Lahiri DK, Utsuki T, Chen D, et al. Nicotine reduces the secretion of Alzheimer's beta-amyloid precursor protein containing β-amyloid peptide in the rat without altering synaptic proteins. Ann NY Acad Sci 2002;965:364-372.
86. Nordberg A, Hellstrom-Lindahl E, Lee M, et al. Chronic nicotine treatment reduces β-amyloidosis in the brain of a mouse model of Alzheimer's disease (APPsw). J Neurochem 2002;81:655-658.
87. Harkany T, Varga C, Grosche J, et al. Distinct subtypes of nucleus basalis neurons exhibit similar sensitivity to excitotoxicity. Neuroreport 2002;13:767-772.
88. Bigl M, Apelt J, Luschenkina EA, Lange-Dohna C, Rossner S, Schliebs R. Expression of beta-secretase mRNA in transgenic mouse brain with Alzheimer plaque pathology. Neurosci Lett 2000;292:107-110.
89. Hartlage-Rübsamen M, Zeitschel U, Apelt J, et al. Astrocytic expression of the Alzheimer's disease β-secretase (BACE1) is stimulus-dependent. Glia 2003;41:169-179.
90. Pietrini P, Alexander GE, Furey ML, Hampel H, Guazzelli M. The neurometabolic landscape of cognitive decline: in vivo studies with positron emission tomography in Alzheimer's disease. Int J Psychophysiol 2000;37:87-98.
91. Bigl M, Brückner MK, Arendt T, Bigl V, Eschrich K. Activities of key glyco-lytic enzymes in the brains of patients with Alzheimer's disease. J Neural Transm 1999;106:499-511.
92. Harr SD, Simonian NA, Hyman BT. Functional alterations in Alzheimer's disease: decreased glucose transporter 3 immunoreactivity in the perforant pathway terminal zone. J Neuropathol Exp Neurol 1995;54:38-41.
93. Mooradian AD, Chung HC, Shah GN. GLUT-1 expression in the cerebra of patients with Alzheimer's disease. Neurobiol Aging 1997;18:469-474.
94. Simpson IA, Chundu KR, Davies-Hill T, Honer WG, Davies P. Decreased concentrations of GLUT1 and GLUT3 glucose transporters in the brains of patients with Alzheimer's disease. Ann Neurol 1994;35:546-551.
95. Frölich L, Blum-Degen D, Bernstein HG, et al. Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease. J Neural Transm 1998;105:423-438.
96. Frölich L, Blum-Degen D, Riederer P, Hoyer S. A disturbance in the neuronal insulin receptor signal transduction in sporadic Alzheimer's disease. Ann NY Acad Sci 1999;893:290-293.
97. Hoyer S. The brain insulin signal transduction system and sporadic (type II) Alzheimer disease: an update. J Neural Transm 2002;109:341-360.
98. Meier-Ruge WA, Bertoni-Freddari C. Pathogenesis of decreased glucose turnover and oxidative phosphorylation in ischemic and trauma-induced dementia of the Alzheimer type. Ann NY Acad Sci 1997;826:229-241.
99. Durkin TP, Messier C, de Boer P, Westerink BH. Raised glucose levels enhance scopolamine-induced acetylcholine overflow from the hippocampus: an in vivo microdialysis study in the rat. Behav Brain Res 1992;49:181-188.
100. Kopf SR, Baratti CM. Effects of posttraining administration of glucose on retention of a habituation response in mice: participation of a central cholin-ergic mechanism. Neurobiol Learn Mem 1996;65:253-260.
101. Kopf SR, Baratti CM. Memory-improving actions of glucose: involvement of a central cholinergic muscarinic mechanism. Behav Neural Biol 1994;62:237-243.
102. Lawson CJ, Homewood J, Taylor AJ. The effects of l-glucose on memory in mice are modulated by peripherally acting cholinergic drugs. Neurobiol Learn Mem 2002;77:17-28.
103. Ragozzino ME, Pal SN, Unick K, Stefani MR, Gold PE. Modulation of hip-pocampal acetylcholine release and spontaneous alternation scores by intrahippocampal glucose injections. J Neurosci 1998;18:1595-15601.
104. Stone WS, Rudd RJ, Gold PE. Glucose attenuation of atropine-induced deficits in paradoxical sleep and memory. Brain Res 1995;694:133-138.
105. Blin J, Ivanoiu A, Coppens A, et al. Cholinergic neurotransmission has different effects on cerebral glucose consumption and blood flow in young normals, aged normals, and Alzheimer's disease patients. Neuroimage 1997;6:335-343.
106. Browne SE, Lin L, Mattsson A, Georgievska B, Isacson O. Selective antibody-induced cholinergic cell and synapse loss produce sustained hippocam-pal and cortical hypometabolism with correlated cognitive deficits. Exp Neurol 2001;170:36-47.
107. De Micheli E, Lamour Y, Bassant MH, Soncrant TT. Sustained cortical metabolic responsivity to physostigmine after nucleus basalis magnocellularis ablation in rats. Brain Res 1993;615:80-86.
108. Katsumi Y, Hayashi T, Oyanagi C, et al. Glucose metabolism in the rat frontal cortex recovered without the recovery of choline acetyltransferase activity after lesioning of the nucleus basalis magnocellularis. Neurosci Lett 2000;280:9-12.
109. Lamour YA, Holloway HW, Larson DM, Soncrant TT. The effect of lesions of the nucleus basalis magnocellularis on local brain glucose utilization in the rat: time course. Neurodegeneration 1993;2:41-50.
110. Orzi F, Diana G, Casamenti F, Palombo E, Fieschi C. Local cerebral glucose utilization following unilateral and bilateral lesions of the Nucleus basalis magnocellularis in the rat. Brain Res 1988;462:99-103.
111. Ouchi Y, Fukuyama H, Ogawa M, et al. Cholinergic projection from the basal forebrain and cerebral glucose metabolism in rats: a dynamic PET study. J Cereb Blood Flow Metab 1996;16:34-41.
112. Soncrant TT, Holloway HW, Horwitz B, Rapoport SI, Lamour YA. Effect of nucleus basalis magnocellularis ablation on local brain glucose utilization in the rat: functional brain reorganization. Eur J Neurosci 1992;4:653-662.
113. Apelt J, Leßig, Schliebs R. β-amyloid-associated expression of intercellular adhesion molecule-1 (ICAM-1) in brain cortical tissue of transgenic Tg2576 mice. Neurosci Lett 2002;329:111-115.
114. Klingner M, Apelt J, Kumar A, et al. Alterations in cholinergic and non-cho-linergic neurotransmitter receptor densities in transgenic Tg2576 mouse brain with β-amyloid plaque pathology. Int J Dev Neurosci 2003;21:357-369.
115. Bigl M, Apelt J, Eschrich K, Schliebs R. Cortical glucose metabolism is altered in aged transgenic Tg2576 mice that demonstrate Alzheimer plaque pathology. J Neural Transm 2003;110:77-94.
116. Szutowicz A. Aluminum, NO and nerve growth factor neurotoxicity in cho-linergic neurons. J Neurosci Res 2001;66:1009-1018.
117. Tomaszewicz M, Roßner S, Schliebs R, Cwikowska J, A. Szutowicz A. Changes in cortical acetyl-CoA metabolism after selective basal forebrain cho-linergic degeneration by 192 IgG-saporin. J Neurochem 2003;87:318-324.
118. Zeitschel U, Schliebs R, Roßner S, Bigl V, Eschrich K, Bigl M. Changes in activity and expression of phosphofructokinase in different rat brain region after basal forebrain cholinergic lesion. J Neurochem 2002;83:371-380.
119. Mehlhorn G, Loffler T, Apelt J, et al. Glucose metabolism in cholinoceptive cortical rat brain regions after basal forebrain cholinergic lesion. Int J Dev Neurosci 1998;16:675-690.
120. Bassant MH, Poindessous-Jazat F, Schmidt BH. Sustained effect of metrifonate on cerebral glucose metabolism after immunolesion of basal fore-brain cholinergic neurons in rats. Eur J Pharmacol 2000;387:151-162.
121. Sato A, Sato Y. Cholinergic neural regulation of regional cerebral blood flow. Alzheimer Dis Assoc Disord 1995;9:28-38.
122. Heininger K. Unifying hypothesis of Alzheimer's disease. IV. Causation and sequence of events. Rev Neurosci 2000;11:213-328.
123. Husain K, Ansari RA. Influence of cholinergic and adrenergic blocking drugs on hyperglycemia and brain glycogenolysis in diazinon-treated animals. Can J Physiol Pharmacol 1988;66:1144-1147.
124. Duelli R, Staudt R, Maurer MH, Kuschinsky W. Local transport kinetics of glucose during acute and chronic nicotine infusion in rat brains. J Neural Transm 1998;105:1017-1028.
125. Peterson C. Tetrahydroaminoacridine increases acetylcholine synthesis and glucose oxidation by mouse brain slices in vitro. Neurosci Lett 1990;115:274-278.
126. Marie S, Diaz-Guerra MJ, Miquerol L, Kahn A, Iynedjian PB. The pyruvate kinase gene as a model for studies of glucose-dependent regulation. J Biol Chem 1993;268:23, 881-23, 890.
127. Perry VH, Bolton SJ, Anthony DC, Betmouni S. The contribution of inflammation to acute and chronic neurodegeneration. Res Immunol 1998;149:721-725.
128. Akiyama H, Barger S, Barnum S, et al. Inflammation and Alzheimer's disease. Neurobiol Aging 2000;21:383-421.
129. Lüth HL, Apelt J, Ihunwo A, Schliebs R. Degeneration of β-amyloid-associated cholinergic structures in transgenic APPSW mice. Brain Res 2003;977:16-22.
130. McGeer PL, McGeer EG, Yasojima K. Alzheimer disease and neuroinflamma-tion. J Neural Transm 2000;59(suppl):53-57.
131. Wenk GL, Willard LB. The neuronal mechanisms underlying cholinergic cell death within the basal forebrain. Int J Dev Neurosci 1998;16:729-735.
132. Willard LB, Hauss-Wegrzyniak B, Wenk GL. Pathological and biochemical consequences of acute and chronic neuroinflammation within the basal fore-brain cholinergic system of rats. Neuroscience 1999;88:193-200.
133. Bauer J, Strauss S, Schreiter-Gasser U, et al. Interleukin-6 and a-2-macroglo-bulin indicate an acute-phase state in Alzheimer's disease cortices. FEBS Lett 1991;285:111-114.
134. Griffin W S T, Sheng JG, Roberts GW, Mrak RE. Interleukin-1 expression in different plaque types in Alzheimer's disease: significance in plaque evolution. J Neuropathol Exp Neurol 1995;54:276-281.
135. McGeer EG, McGeer PL. The importance of inflammatory mechanisms in Alzheimer's disease. Exp Gerontol 1998;33:371-378.
136. Lemke R, Hartig W, Roßner S, Bigl V, Schliebs R. Interleukin-6 is not expressed in activated microglia and in reactive astrocytes in response to lesion of rat basal forebrain cholinergic system as demonstrated by combined in situ hybridization and immunocytochemistry. J Neurosci Res 1998;51:223-236.
137. Lemke R, Gadient R A, Patterson PH, Bigl V, Schliebs R. Leukemia inhibitory factor (LIF) mRNA-expressing neuronal subpopulations in rat basal forebrain, Neurosci Lett 1997;229:69-71.
138. Hartlage-Rübsamen M, Lemke R, Schliebs R. Interleukin-1beta, inducible nitric oxide synthase, and nuclear factor-KB are induced in morphologically distinct microglia after rat hippocampal lipopolysaccharide/ interferon-gamma injection. J Neurosci Res 1999;57:388-398.
139. Murphy M, Dutton R, Koblar S, Cheema S, Bartlett P. Cytokines which signal through the LIF receptor and their actions in the nervous system. Prog Neurobiol 1997;52:355-378.
140. Cheema SS, Arumugam D, Murray SS, Bartlett PF. Leukemia inhibitory factor maintains choline acetyltransferase expression in vivo. Neuroreport 1998;9:363-366.
141. Arvin B, Neville LF, Barone FC, Feuerstein GZ. The role of inflammation and cytokines in brain injury. Neurosci Biobehav Rev 1996;20:445-452.
142. Gadient RA, Otten UH. Interleukin-6 (IL-6)-a molecule with both beneficial and destructive potentials. Prog Neurobiol 1997;52:379-390.
143. Gruol DL, Nelson TE. Physiological and pathological roles of interleukin-6 in the central nervous system. Mol Neurobiol 1997;15:307-339.
144. Minami M, Kuraishi Y, Satoh M. Effects of kainic acid on messenger RNA levels of IL-1 (3, IL-6, TNF a and LIF in the rat brain. Biochem Biophys Res Commun 1991;176:593-598.
145. Marquette C, Van Dam AM, Ceccaldi PE, Weber P, Haour F, Tsiang H. Induction of immunoreactive interleukin-1 beta and tumor necrosis factor-a in the brains of rabies virus infected rats. J Neuroimmunol 1996;68:45-51.
146. Kreutzberg GW. Microglia: a sensor for pathological events in the CNS. Trends Neurosci 1996;19:312-318.
147. Brown HC, Perry VH. Differential adhesion of macrophages to white and grey matter in an in vitro assay. Glia 1998;23:361-373.
148. Kloss CU, Werner A, Klein MA, et al. Integrin family of cell adhesion molecules in the injured brain: regulation and cellular localization in the normal and regenerating mouse facial motor nucleus. J Comp Neurol 1999;411:162-178.
149. Hailer NP, Bechmann I, Heizmann S, Nitsch R. Adhesion molecule expression on phagocytic microglial cells following anterograde degeneration of perforant path axons. Hippocampus 1997;7:341-349.
150. Jones LS, Grooms SY. Normal and aberrant functions of integrins in the adult central nervous system. Neurochem Int 1997;31:587-595.
151. Springer TA. Adhesion receptors of the immune system. Nature 1990;346:425-434.
152. Lee SJ, Benveniste EN. Adhesion molecule expression and regulation on cells of the central nervous system. J Neuroimmunol 1999;98:77-88.
153. Cotman CW, Hailer NP, Pfister KK, Soltesz I, Schachner M. Cell adhesion molecules in neural plasticity and pathology: similar mechanisms, distinct organizations? Prog Neurobiol 1998;55:659-669.
154. Verbeek MM, Otte-Holler I, Wesseling P, Ruiter DJ, de Waal RM. Differential expression of intercellular adhesion molecule-1 (ICAM-1) in the A β-containing lesions in brains of patients with dementia of the Alzheimer type. Acta Neuropathol (Berl) 1996;91:608-615.